| BCBS Highmark West Virginia | Margetuximab-cmkb (Margenza) | 2025-10-01 |
| BCBS Highmark West Virginia | Revakinagene taroretcel-lwey (Encelto) | 2025-10-01 |
| BCBS Highmark NY and West NY | Datopotamab deruxtecan-dlnk (Datroway) | 2025-10-01 |
| BCBS Highmark NY and West NY | Fulvestrant (Faslodex) | 2025-10-01 |
| HealthPartners | Oncology ** - denosumab and biosimilars | 2025-10-01 |
| UHC Commercial Medical & Drug | Antiemetics for Oncology – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Encelto™ (Revakinagene Taroretcel-Lwey) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Lemtrada® (Alemtuzumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Long-Acting Injectable Antiretroviral Agents for HIV – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Medical Benefit Therapeutic Equivalent Medications – Excluded Drugs – Commercial Medical Benefit Drug Policy | 2025-10-01 |